This effort, undertaken by Bristol Myers Squibb and agency partner Real Chemistry, is part of the Champions in Care campaign.

Dark Blue Therapeutics ("Dark Blue"), a discovery and development biotech company pioneering the next generation of precision oncology medicines, has been acquired by Amgen (NASDAQ: AMGN).

Amgen’s acquisition of Dark Blue Therapeutics adds a first-in-class leukemia program that aligns with the company’s growing ...

New analysis of a Phase 3 study of daridorexant shows that 50 mg improved both sleep and daytime functioning compared to ...

A few 2025 trials pointed in the same direction: toward treatments built to modify disease biology and better ways to measure ...

ProLogium Technology, a leader in solid-state battery R&D and mass production, today announced that it will co-exhibit with FEV Group, a globally leading innovation driver for mobility solutions and ...

Bristol Myers (BMY) stock is in focus as the firm to offer its Pfizer (PFE)-partnered Eliquis, free to Medicaid as part of a U.S. pricing deal. Read more here.

New analysis of a Phase 3 study of daridorexant shows that 50 mg improved both sleep and daytime functioning compared to placebo in women during menopausal transition ageBrigham and Women's Hospital t ...

The recall is part of the FDA's active investigation into frozen shrimp products that could potentially be contaminated with ...

This year, the government has decided to include a driver monitoring system in the Korean New Car Assessment Program (KNCAP).

Slated for a Dec. 26 decision on Cytokinetics’ aficamten, the FDA has delivered an early Christmas present, awarding the South San Francisco biotech its first U.S. nod since its 1997 founding. | ...

New Jersey-based pharma companies joined White House drug pricing deals aimed at lowering prescription drug costs under Trump’s policy.